Table 1.
BTCE Clinical Trials in Multiple Myeloma.
| BiTE Name | BiTE Target | Phase | Status | Clinical Trial Number |
Completion Date |
|---|---|---|---|---|---|
| Blinatumomab | CD19 | I | Terminated | NCT03173430 | 2019 |
| AMG 424 | CD38 | I/II | Recruiting | NCT03445663 | 2022 |
| GBR 1342 | CD38 | I/II | Recruiting | NCT03309111 | 2021 |
| BFCR4350A | FcRH5 | I | Recruiting | NCT03275103 | 2022 |
| AMG 420 | BCMA | I | Completed/ Active |
NCT02514239/ NCT03836053 |
2020/ 2025 |
| AMG 701 | BCMA | I/II | Recruiting | NCT03287908 | 2025 |
| CC-93269 | BCMA | I | Recruiting | NCT03486067 | 2026 |
| Elranatamab (PF-06863135) | BCMA | I/II | Recruiting/ Active |
NCT03269136/ NCT04649359 |
2023 |
| REGN5458 | BCMA | I/II | Recruiting | NCT03761108 | 2022 |
| TNB-383B | BCMA | I | Recruiting | NCT03933735 | 2021 |